Treatment and Outcomes of Children With Febrile Urinary Tract Infection Due to Extended Spectrum Beta-lactamase-producing Bacteria in Europe: TOO CUTE Study.
Adolescent
Anti-Bacterial Agents
/ pharmacology
Bacterial Infections
/ drug therapy
Child
Child, Preschool
Drug Resistance, Bacterial
Epsilonproteobacteria
/ drug effects
Female
Humans
Infant
Infant, Newborn
Male
Pyelonephritis
Retrospective Studies
Treatment Outcome
Urinary Tract Infections
/ drug therapy
beta-Lactamases
/ metabolism
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
19
9
2020
medline:
27
7
2021
entrez:
18
9
2020
Statut:
ppublish
Résumé
The prevalence of extended-spectrum beta-lactamase producing Εnterobacteriaceae (ESBL-PE) is increasing globally. ESBL-PE are an important cause of urinary tract infections (UTIs) in children. We aimed to characterize the clinical presentation, treatment and outcomes of childhood UTI caused by ESBL-PE in Europe. Multicenter retrospective cohort study. Children 0 to 18 years of age with fever, positive urinalysis and positive urine culture for an ESBL-PE uropathogen, seen in a participating hospital from January 2016 to July 2017, were included. Primary outcome measure: day of defervescence was compared between (1) initial microbiologically effective treatment (IET) versus initial microbiologically ineffective treatment (IIT) and (2) single initial antibiotic treatment versus combined initial antibiotic treatment. Clinical and microbiologic failure of initial treatment. We included 142 children from 14 hospitals in 8 countries. Sixty-one children had IET and 77 IIT. There was no statistical difference in time to defervescence for effective/ineffective groups (P = 0.722) and single/combination therapy groups (P = 0.574). Two of 59 (3.4%) and 4/66 (6.1%) patients exhibited clinical failure during treatment (P = 0.683) when receiving IET or IIT, respectively. Eight of 51 (15.7%) receiving IET and 6/58 (10.3%) receiving IIT patients (P = 0.568) had recurring symptoms/signs suggestive of a UTI. Recurrence of a UTI occurred 15.5 days (interquartile range, 9.0-19.0) after the end of treatment. Time to defervescence and clinical failure did not differ between IET/IIT groups. Non-carbapenem beta-lactam antibiotics may be used for the empiric treatment of ESBL febrile UTIs, until susceptibility testing results become available.
Sections du résumé
BACKGROUND
The prevalence of extended-spectrum beta-lactamase producing Εnterobacteriaceae (ESBL-PE) is increasing globally. ESBL-PE are an important cause of urinary tract infections (UTIs) in children. We aimed to characterize the clinical presentation, treatment and outcomes of childhood UTI caused by ESBL-PE in Europe.
METHODS
Multicenter retrospective cohort study. Children 0 to 18 years of age with fever, positive urinalysis and positive urine culture for an ESBL-PE uropathogen, seen in a participating hospital from January 2016 to July 2017, were included.
MAIN OUTCOME MEASURES
Primary outcome measure: day of defervescence was compared between (1) initial microbiologically effective treatment (IET) versus initial microbiologically ineffective treatment (IIT) and (2) single initial antibiotic treatment versus combined initial antibiotic treatment.
SECONDARY OUTCOME MEASURES
Clinical and microbiologic failure of initial treatment.
RESULTS
We included 142 children from 14 hospitals in 8 countries. Sixty-one children had IET and 77 IIT. There was no statistical difference in time to defervescence for effective/ineffective groups (P = 0.722) and single/combination therapy groups (P = 0.574). Two of 59 (3.4%) and 4/66 (6.1%) patients exhibited clinical failure during treatment (P = 0.683) when receiving IET or IIT, respectively. Eight of 51 (15.7%) receiving IET and 6/58 (10.3%) receiving IIT patients (P = 0.568) had recurring symptoms/signs suggestive of a UTI. Recurrence of a UTI occurred 15.5 days (interquartile range, 9.0-19.0) after the end of treatment.
CONCLUSIONS
Time to defervescence and clinical failure did not differ between IET/IIT groups. Non-carbapenem beta-lactam antibiotics may be used for the empiric treatment of ESBL febrile UTIs, until susceptibility testing results become available.
Identifiants
pubmed: 32947600
doi: 10.1097/INF.0000000000002838
pii: 00006454-202012000-00012
doi:
Substances chimiques
Anti-Bacterial Agents
0
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1081-1087Références
Centers for Disease Control and Prevention. Office of Infectious Disease Antibiotic Resistance Threats in the United States, 2013. 2013. Available at: http://Www.Cdc.Gov/Drugresistance/Threat-Report-2013. Accessed March 31, 2019.
World Health Organization. Antimicrobial Resistance: Global Report on Surveillance. 2014. Available at: http://Www.Who.Int/Drugresistance/Documents/Surveillancereport/En. Accessed March 31, 2019.
Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–686.
Pana ZD, Zaoutis T. Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?. F1000Research. 2018;7:1347.
Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis. 2014;58:1439–1448.
European Centre for Disease Prevention and Control. Surveillance of Antimicrobial Resistance in Europe – Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. 2018. Stockholm: ECDC; Available at: https://Ecdc.Europa.Eu/Sites/Portal/Files/Documents/EARS-Net-Report-2017-Update-Jan-2019.Pdf. Accessed April 21, 2019.
Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis. 2006;56:427–436.
Morrissey I, Hackel M, Badal R, et al. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceuticals. Basel). 2013;6:1335–1346.
Lukac PJ, Bonomo RA, Logan LK. Extended-spectrum β-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat. Clin Infect Dis. 2015;60:1389–1397.
Flokas ME, Detsis M, Alevizakos M, et al. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: a systematic review and meta-analysis. J Infect. 2016;73:547–557.
MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014;9:232–238.
Roberts KB. Subcommittee on Urinary Tract Infection., Steering Committee on Quality Improvement and Management. Urinary Tract Infection: clinical practice guideline for the diagnosis and management of an initial UTI in febrile infants and young children. Pediatrics. 2011;128:e749–e770.
National Institute for Health and Care Excellence (NICE). Urinary Tract Infection in under 16s: Diagnosis and Management. 2007. Available at: https://Www.Nice.Org.Uk/Guidance/Cg54/Evidence/Full-Guideline-Pdf-196566877. Accessed April 22, 2019.
World Health Organization. Model List of Essential Medicines for Children, 7th List, 2019. 2019.Geneva: World Health Organization;
Jerardi KE, Auger KA, Shah SS, et al. Discordant antibiotic therapy and length of stay in children hospitalized for urinary tract infection. J Hosp Med. 2012;7:622–627.
European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints and dosing of antibiotics.Available at: http://www.eucast.org/clinical_breakpoints/. Accessed September 3, 2020.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing.Available at: https://clsi.org/standards/products/microbiology/documents/ Accessed September 3, 2020.
Madhi F, Jung C, Timsit S, et al.; Urinary-tract Infection due to Extended-Spectrum Beta-lactamase–producing Enterobacteriaceae in Children Group. Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: a French prospective multicenter study. PLoS One. 2018;13:e0190910.
Seo YB, Lee J, Kim YK, et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis. 2017;17:404.
Vazouras K, Basmaci R, Bielicki J, et al. Antibiotics and cure rates in childhood febrile urinary tract infections in clinical trials: a systematic review and meta-analysis. Drugs. 2018;78:1593–1604.
Zykov IN, Sundsfjord A, Småbrekke L, et al. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010–2011. Infect Dis. 2016;48:99–107.
Koçak M, Büyükkaragöz B, Çelebi Tayfur A, et al. Causative pathogens and antibiotic resistance in children hospitalized for urinary tract infection. Pediatr Int. 2016;58:467–471.
Pérez Heras I, Sanchez-Gomez JC, Beneyto-Martin P, et al. Community-onset extended-spectrum β-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016: prevalence, risk factors, and resistances. Medicine. Baltimore). 2017;96:e8571.
Vardakas KZ, Tansarli GS, Rafailidis PI, et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793–2803.
Perez F, Bonomo RA. Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?. Clin Infect Dis. 2012;54:175–177.
Bingen E, Bidet P, Birgy A, et al. In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection. J Clin Microbiol. 2012;50:2540–2541.
Ramos-Martínez A, Alonso-Moralejo R, Ortega-Mercader P, et al. Pronóstico de las infecciones urinarias con tratamiento antibiótico discordante. Rev Clínica Esp. 2010;210:545–549.
Kim SH, Oh S, Huh K, et al. Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales. Eur J Clin Microbiol Infect Dis. 2019;38:937–944.
Wang ME, Lee V, Greenhow TL, et al. Clinical response to discordant therapy in third-generation cephalosporin-resistant UTIs. Pediatrics. 2020;145:e20191608.
Hyun HS, Kim JH, Cho MH, et al. Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children. Pediatr Nephrol. 2019;34:2399–2407.
Tratselas A, Iosifidis E, Ioannidou M, et al. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children. Pediatr Infect Dis J. 2011;30:707–710.
Long SS, Pickering LK, Prober CG. Principles and Practice of Pediatric Infectious Diseases. 2009.3rd edNew York, NY: Churchill Livingstone/Elsevier;
Bhalerao S, Kadam P. Sample size calculation. Int J Ayurveda Res. 2010;1:55.
European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Final guidance. 2012. Available at: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003417.pdf. Accessed July 17, 2019.
Tratselas A, Simitsopoulou M, Giannakopoulou A, et al. Effect of ceftriaxone on the outcome of murine pyelonephritis caused by extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2014;58:7102–7111.